Coeptis Therapeutics (COEP) Competitors $9.84 -0.06 (-0.61%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$9.72 -0.12 (-1.17%) As of 07/15/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. GLSI, LYEL, IKT, NKTX, FATE, MCRB, ALTS, FTLF, KRRO, and TARAShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Greenwich LifeSciences (GLSI), Lyell Immunopharma (LYEL), Inhibikase Therapeutics (IKT), Nkarta (NKTX), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), ALT5 Sigma (ALTS), FitLife Brands (FTLF), Korro Bio (KRRO), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Greenwich LifeSciences Lyell Immunopharma Inhibikase Therapeutics Nkarta Fate Therapeutics Seres Therapeutics ALT5 Sigma FitLife Brands Korro Bio Protara Therapeutics Coeptis Therapeutics (NASDAQ:COEP) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Which has more volatility & risk, COEP or GLSI? Coeptis Therapeutics has a beta of -0.63, suggesting that its share price is 163% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Do insiders and institutionals believe in COEP or GLSI? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, COEP or GLSI? Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.70Greenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.00 Do analysts recommend COEP or GLSI? Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 286.90%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor COEP or GLSI? In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Greenwich LifeSciences' average media sentiment score of 1.89 beat Coeptis Therapeutics' score of 0.93 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment Coeptis Therapeutics Positive Greenwich LifeSciences Very Positive Is COEP or GLSI more profitable? Coeptis Therapeutics' return on equity of -282.39% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% Greenwich LifeSciences N/A -450.87%-333.18% SummaryGreenwich LifeSciences beats Coeptis Therapeutics on 7 of the 12 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.79M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-1.7020.2228.5719.58Price / SalesN/A290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book6.117.568.135.54Net Income-$10.88M-$55.11M$3.24B$257.73M7 Day Performance7.66%3.81%0.16%-0.08%1 Month Performance19.56%11.60%5.95%8.09%1 Year Performance62.75%-2.11%26.09%13.02% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.396 of 5 stars$9.84-0.6%N/A+62.4%$34.79MN/A-1.702Gap DownGLSIGreenwich LifeSciences2.154 of 5 stars$10.18-5.8%$39.00+283.1%-35.6%$136.11MN/A-8.083High Trading VolumeLYELLyell Immunopharma3.4652 of 5 stars$9.10-5.9%$15.00+64.9%-73.5%$134.68M$65K-0.36270News CoverageIKTInhibikase Therapeutics1.2001 of 5 stars$1.80-7.5%$6.50+262.1%+20.8%$133.44MN/A-0.676NKTXNkarta1.8206 of 5 stars$1.84-2.9%$14.33+681.1%-74.1%$130.21MN/A-1.22140Positive NewsFATEFate Therapeutics3.5165 of 5 stars$1.14-0.4%$3.83+237.7%-71.0%$130.08M$13.34M-0.76550MCRBSeres Therapeutics3.4432 of 5 stars$14.54-2.1%$73.67+406.8%-38.4%$127.12MN/A-3.16330Positive NewsALTSALT5 Sigma0.1329 of 5 stars$7.15+2.8%N/AN/A$124.35M$18.05M0.00170FTLFFitLife Brands4.0471 of 5 stars$13.18+0.7%$20.50+55.5%-19.3%$123.81M$64.47M15.7020KRROKorro Bio1.5233 of 5 stars$12.73-1.9%$102.43+704.9%-74.3%$119.49M$2.27M-1.3570TARAProtara Therapeutics2.1423 of 5 stars$3.07-3.0%$20.50+568.8%+28.2%$118.25MN/A-1.7830Positive News Related Companies and Tools Related Companies Greenwich LifeSciences Alternatives Lyell Immunopharma Alternatives Inhibikase Therapeutics Alternatives Nkarta Alternatives Fate Therapeutics Alternatives Seres Therapeutics Alternatives ALT5 Sigma Alternatives FitLife Brands Alternatives Korro Bio Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
